Dr. Lorenzo Gianni - Oncologia Rimini

More documents

Recommendations

Info

Sunitinib vs Capecitabina nell’ABC: PFS e OS Barrios C, et al. SABCS 2009; #46 SABCS09_GS4_06
CIRG/TORI 010: Fase II-R: wP ± motesanib: 1a linea HER2-ve MBC Mackey J, et al. SABCS 2009; #47 SABCS09_GS4_07
Page 1 and 2: Caratteristiche biologiche e ruolo
Page 3 and 4: VEGF e recettori VEGF-R • Famigli
Page 5 and 6: Espressione VEGF nella malattia pre
Page 8 and 9: Angiogenesis and lymphangiogenesis
Page 10 and 11: Transduzione del segnale e processi
Page 12 and 13: Effetto inibitori angiogenesi e pos
Page 14 and 15: Metronomic vs conventional scheduli
Page 16 and 17: Rapid Chemotherapy-Induced Acute En
Page 18 and 19: AVF2119g trial CAP 2500 mg CAP + BV
Page 20 and 21: RIBBON-II Brufsky A, Bondarenko IN,
Page 22 and 23: Brufsky A, Bondarenko IN, et al. SA
Page 24 and 25: MO19391 (ATHENA trial) Pierga J, et
Page 26 and 27: MO19391: ATHENA trial 100 Complete
Page 28 and 29: MO19391: ATHENA trial. Elderly vs n
Page 30 and 31: Endpoints di efficacia selezionati:
Page 32 and 33: AVADO trial: disegno, arruolamento
Page 34 and 35: RIBBON-1: PFS Robert N, et al. ASCO
Page 36 and 37: RIBBON-1: ORR e OS Robert N, et al.
Page 38 and 39: N0432:phase II trial of docetaxel w
Page 40 and 41: SABRE: Sunitinib + wP-BV: significa
Page 42 and 43: Bevacizumab + Letrozole PR as best
Page 44 and 45: SUN 1064 study Bergh J. ASCO 2010:
Page 48 and 49: CIRG/TORI 010: risultati (ITT) wP+P
Page 50 and 51: Sorafenib: studio IIb randomizzato,
Page 52 and 53: SOLTI-0701: studio IIb randomizzato
Page 54 and 55: Baselga J, et al. SABCS 2009. #45 S
Page 56 and 57: Sicurezza BV in pz con metastasi SN
Page 58 and 59: Complicanze chirurgiche BV in neoad
Page 60 and 61: Complicazioni chirurgiche: non sign
Page 62 and 63: Quali ragioni per beneficio < alle
Page 64: Terapie antiangiogenetiche nel ca m

Dr. Lorenzo Gianni - Oncologia Rimini

Create successful ePaper yourself

Delete template?

Save as template?